The CDC to Develop MSI’s Back-Scattering Interferometry Technologyas a Diagnostic Platform for the Detection of Infectious Disease and Typing of Causative Agents

Montara, California, September 9th, 2008- Today, Molecular Sensing, Inc. (MSI), an early stage biotechnology company, announces the signing of a Cooperative Research and Development Agreement (CRADA) with the Centers for Disease Control’s, National Center for HIV/AIDS, Viral Hepatitis, STD and TB Prevention and Vanderbilt University, to develop a diagnostic platform for detection of sexually transmitted diseases (STDs) and other infectious agents. MSI has completed shipment of a pre-production molecular interaction assay system to the CDC to be used in the program.

Professor Darryl J. Bornhop of Vanderbilt University has stated, ”We are pleased to be working with the CDC and Molecular Sensing to develop efficacious assays for the detection of a variety of infectious diseases in a near patient format based upon our landmark work in Back Scattering Interferometry.

The journal Science (September 21, 2007) reported that BSI technology, invented by Dr. Darryl Bornhop, enables free-solution, label-free, and tether-free molecular interaction kinetic and end-point assays at zeptomole levels of sensitivity, using a biosensor with a simple optical train comprised of a He-Ne laser, a microfluidic channel, and a position sensor. Vanderbilt University has exclusively licensed Molecular Sensing to further develop and commercialize BSI technology in the areas of life science research, in vitro diagnostics, as well as a variety of other markets including biodefence, environmental testing, and the detection of food-borne illness.

Scot R. Weinberger, President & CEO of Molecular Sensing commented, “We believe this cooperative agreement with the CDC and the Bornhop lab will provide the means to develop a platform for infectious disease diagnostics, and demonstrate its advantages for near-patient testing. The vision of Near-patient testing is to enable a more rapid response to illness, resulting in earlier access to treatment and support, especially within populations where there is a marked risk of patients being lost to follow-up. While recent technology advancements have fueled an expansion of potential near patient tests, the benefits these tests offer are often reduced by their accuracy when compared to with standard laboratory results. The goal of our cooperative work with the CDC is to leverage the inherent strengths of BSI technology to create a truly enabling near patient platform, consistent with the needs and demands of today’s healthcare enterprise.”

About Molecular Sensing

Molecular Sensing, Inc. is an early stage biotechnology company, located in the San Francisco Bay area, dedicated to the creation of molecular interaction products that deliver free solution label-free, tether-free kinetic and end-point assays. MSI’s mission is to become a leader in the emerging field of Personalized Medicine, beginning with a focus on validating our technology in research applications involving biomarker discovery and assay development. Our initial market focus is in academic, government and industrial laboratories. While our first products are aimed at research use, our technology is particularly adaptable to hand-held point-of-care devices and assays for clinical diagnostics.

MSI’s Lighthouse Early Access Program (LEAP) is a fee-based product early access program designed to provide a pre-production MSI molecular interaction assay system and customized collaboration agreement partnership with major laboratories in life science basic and translational research, clinical diagnostics and pharmaceutical R&D to develop and validate enabling applications and instrumentation improvements.

For more information, please see www.molsense.com.